A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) - Full Text View

A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.

Sponsors and Collaborators:	Laboratorios Almirall, S.A. Forest Laboratories
Information provided by:	Laboratorios Almirall, S.A.
ClinicalTrials.gov Identifier:	NCT00363896

Purpose

To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.

Condition	Intervention	Phase
Chronic Obstructive Pulmonary Disease	Drug: Aclidinium bromide	Phase III

MedlinePlus related topics:

COPD (Chronic Obstructive Pulmonary Disease)

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Randomized, Double-Blind, Placebo Control, Parallel Assignment

Official Title:	Clinical Trial Assessing Efficacy and Safety of LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

Further study details as provided by Laboratorios Almirall, S.A.:

Primary Outcome Measures:

Secondary Outcome Measures:

Study Start Date:

August 2006

Eligibility

Criteria

Inclusion Criteria:

Males and females aged ≥ 40 years with a clinical diagnosis of moderate to severe stable COPD

Exclusion Criteria:

History or current diagnosis of asthma, recent respiratory tract infection or acute COPD exacerbation, life expectancy of less than 1 year, known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00363896

Locations

Sponsors and Collaborators

Laboratorios Almirall, S.A.

Forest Laboratories

Investigators


Study Director:	Almirall R & D	Almirall Prodesfarma

More Information

Sponsor web site This link exits the ClinicalTrials.gov site

Co-Sponsor web site This link exits the ClinicalTrials.gov site

Study ID Numbers:	CT000740
First Received:	August 10, 2006
Last Updated:	July 10, 2008
ClinicalTrials.gov Identifier:	NCT00363896
Health Authority:	Belgium: Directorate general for the protection of Public health: Medicines

Keywords provided by Laboratorios Almirall, S.A.:

COPD

Lung function

Exacerbations

Quality of Life

Study placed in the following topic categories:

Lung Diseases, Obstructive

Respiratory Tract Diseases

Bromides

Lung Diseases

Quality of Life

Pulmonary Disease, Chronic Obstructive

ClinicalTrials.gov processed this record on October 10, 2008